Free tool
FAERS Monitor: Twyneo
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214902 or its brand name (Twyneo, Benzoyl Peroxide, Tretinoin). Reports on generic versions are filed under their own applications.
Reports
38
Serious
2
5% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- skin burning sensation7
- acne6
- erythema6
- dry skin5
- inappropriate schedule of product administration5
- intentional product misuse4
- pain of skin4
- poor quality product administered4
- pruritus4
- drug ineffective3
- product colour issue3
- underdose3
- dermatitis2
- dry eye2
- intentional underdose2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 10 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product colour issueSignal | 3 | 323.7 | 109.2 | 669 |
| poor quality product administeredSignal | 4 | 210.1 | 83.1 | 637 |
| intentional underdose | 2 | 151.6 | 39.3 | 168 |
| pain of skinSignal | 4 | 82.2 | 32.5 | 245 |
| skin burning sensationSignal | 7 | 54.1 | 27.7 | 315 |
| dermatitis | 2 | 52.8 | 13.7 | 57 |
| acneSignal | 6 | 43.8 | 21.0 | 211 |
| intentional product misuseSignal | 4 | 25.3 | 10.0 | 71 |
| underdoseSignal | 3 | 22.7 | 7.7 | 43 |
| dry eye | 2 | 22.2 | 5.8 | 22 |
| dry skinSignal | 5 | 20.7 | 9.2 | 76 |
| erythemaSignal | 6 | 16.2 | 7.8 | 72 |
| inappropriate schedule of product administrationSignal | 5 | 15.4 | 6.8 | 54 |
| pruritusSignal | 4 | 5.8 | 2.3 | 12 |
| drug ineffective | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.